SNOA vs. AKBA
SNOA (Sonoma Pharmaceuticals, Inc.) and AKBA (Akebia Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — SNOA in Drug Manufacturers - Specialty & Generic, AKBA in Biotechnology. Over the past 10 years, SNOA returned -47.30%/yr vs -17.23%/yr for AKBA. Their 0.12 correlation means their historical movements had little consistent relationship.
Performance
SNOA vs. AKBA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNOA achieves a -69.78% return, which is significantly lower than AKBA's -18.01% return. Over the past 10 years, SNOA has underperformed AKBA with an annualized return of -47.30%, while AKBA has yielded a comparatively higher -17.23% annualized return.
SNOA
- 1D
- -2.65%
- 1M
- -9.09%
- 6M
- -66.46%
- YTD
- -69.78%
- 1Y
- -63.21%
- 3Y*
- -62.70%
- 5Y*
- -61.74%
- 10Y*
- -47.30%
- ALL TIME*
- -42.21%
AKBA
- 1D
- -2.22%
- 1M
- 6.45%
- 6M
- -6.38%
- YTD
- -18.01%
- 1Y
- -64.52%
- 3Y*
- -10.48%
- 5Y*
- -11.78%
- 10Y*
- -17.23%
- ALL TIME*
- -20.61%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $2.65M | $4.21M | $5.57M | |
| $30.86K | $69.71K | $139.87K |
SNOA vs. AKBA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNOA Sonoma Pharmaceuticals, Inc. | -69.78% | 35.32% | -25.44% | -83.89% | -75.44% | -37.19% | 66.51% | -32.01% | -86.93% | 8.13% |
AKBA Akebia Therapeutics, Inc. | -18.01% | -15.26% | 53.23% | 114.90% | -74.47% | -19.29% | -55.70% | 14.29% | -62.81% | 42.84% |
Correlation
The correlation between SNOA and AKBA is 0.28, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.28 |
Correlation (3Y) Balances recent behavior with more history. | 0.19 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.16 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.14 |
Correlation (All Time) Calculated using the full available price history since Mar 20, 2014 | 0.12 |
The correlation between SNOA and AKBA shifts across timeframes, from 0.12 (all time) to 0.28 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
SNOA:
$1.85M
AKBA:
$354.10M
SNOA:
-$2.01
AKBA:
-$0.08
SNOA:
0.10
AKBA:
1.53
SNOA:
$17.72M
AKBA:
$232.40M
SNOA:
$6.76M
AKBA:
$188.28M
SNOA:
-$3.31M
AKBA:
$2.84M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNOA vs. AKBA — Risk / Return Rank
SNOA
AKBA
SNOA vs. AKBA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sonoma Pharmaceuticals, Inc. (SNOA) and Akebia Therapeutics, Inc. (AKBA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SNOA | AKBA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.23 | ||
| Sortino ratioReturn per unit of downside risk | +0.21 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 0.84 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | -0.78 | -0.84 | +0.06 |
| Martin ratioReturn relative to average drawdown | -1.22 | -1.14 | -0.08 |
Loading charts...
Drawdowns
SNOA vs. AKBA - Drawdown Comparison
The maximum SNOA drawdown since its inception was -100.00%, roughly equal to the maximum AKBA drawdown of -99.14%. Use the drawdown chart below to compare losses from any high point for SNOA and AKBA.
Loading charts...
Drawdown Indicators
| SNOA | AKBA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -99.14% | -0.86% |
Max Drawdown (1Y)Largest decline over 1 year | -81.12% | -76.94% | -4.18% |
Max Drawdown (3Y)Largest decline over 3 years | -95.14% | -78.23% | -16.91% |
Max Drawdown (5Y)Largest decline over 5 years | -99.38% | -92.51% | -6.87% |
Max Drawdown (10Y)Largest decline over 10 years | -99.93% | -98.73% | -1.20% |
Current DrawdownCurrent decline from peak | -100.00% | -95.47% | -4.53% |
Average DrawdownAverage peak-to-trough decline | -91.21% | -77.51% | -13.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.75% | 56.14% | -4.39% |
Volatility
SNOA vs. AKBA - Volatility Comparison
The current volatility for Sonoma Pharmaceuticals, Inc. (SNOA) is 8.91%, while Akebia Therapeutics, Inc. (AKBA) has a volatility of 15.08%. This indicates that SNOA experiences smaller price fluctuations and is considered to be less risky than AKBA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNOA | AKBA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.91% | 15.08% | -6.17% |
Volatility (6M)Calculated over the trailing 6-month period | 66.28% | 51.77% | +14.51% |
Volatility (1Y)Calculated over the trailing 1-year period | 101.42% | 75.75% | +25.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 118.29% | 91.54% | +26.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 103.86% | 84.81% | +19.05% |
Dividends
SNOA vs. AKBA - Dividend Comparison
Neither SNOA nor AKBA has paid dividends to shareholders.
Financials
SNOA vs. AKBA - Financials Comparison
This section allows you to compare key financial metrics between Sonoma Pharmaceuticals, Inc. and Akebia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNOA vs. AKBA - Profitability Comparison
SNOA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Sonoma Pharmaceuticals, Inc. reported a gross profit of 1.65M and revenue of 4.35M. Therefore, the gross margin over that period was 37.9%.
AKBA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Akebia Therapeutics, Inc. reported a gross profit of 41.25M and revenue of 53.54M. Therefore, the gross margin over that period was 77.1%.
SNOA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Sonoma Pharmaceuticals, Inc. reported an operating income of -678.00K and revenue of 4.35M, resulting in an operating margin of -15.6%.
AKBA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Akebia Therapeutics, Inc. reported an operating income of -4.70M and revenue of 53.54M, resulting in an operating margin of -8.8%.
SNOA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Sonoma Pharmaceuticals, Inc. reported a net income of -819.00K and revenue of 4.35M, resulting in a net margin of -18.8%.
AKBA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Akebia Therapeutics, Inc. reported a net income of -9.05M and revenue of 53.54M, resulting in a net margin of -16.9%.
Frequently Asked Questions
SNOA and AKBA have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AKBA has higher volatility (15.08%) compared to SNOA (8.91%). In terms of maximum drawdown, SNOA dropped -100.00% vs AKBA's -99.14%.
SNOA currently has the higher Sharpe Ratio (-0.62 vs -0.85), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNOA and AKBA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer